Michelle A H Sonneveld1, Oscar H Franco1, M Arfan Ikram1, Albert Hofman1, Maryam Kavousi1, Moniek P M de Maat1, Frank W G Leebeek2. 1. From the Department of Hematology (M.A.H.S., M.P.M.d.M., F.W.G.L.), Department of Epidemiology (O.H.F., M.A.I., A.H., M.K.), Department of Neurology (M.A.I.), and Department of Radiology (M.A.I.), Erasmus University Medical Center, Rotterdam, The Netherlands; and Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA (A.H.). 2. From the Department of Hematology (M.A.H.S., M.P.M.d.M., F.W.G.L.), Department of Epidemiology (O.H.F., M.A.I., A.H., M.K.), Department of Neurology (M.A.I.), and Department of Radiology (M.A.I.), Erasmus University Medical Center, Rotterdam, The Netherlands; and Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA (A.H.). f.leebeek@erasmusmc.nl.
Abstract
OBJECTIVE: Von Willebrand Factor (VWF) is a plasma protein that plays a major role in platelet adhesion and aggregation. Large VWF multimers are cleaved into smaller, less coagulant forms by the metalloprotease ADAMTS13 (A Disintegrin And Metalloprotease with ThromboSpondin motif repeats 13). Previous studies have shown that high VWF and low ADAMTS13 levels are associated with cardiovascular disease, but whether these factors are associated with mortality is unclear. Our aim is to establish the association between VWF antigen (VWF:Ag) levels, ADAMTS13 activity, and mortality. APPROACH AND RESULTS: We included 6130 participants of the Rotterdam study, a population-based cohort study among individuals aged ≥55 years. We determined the association between ADAMTS13 activity, VWF:Ag levels, and all-cause and cardiovascular mortality by Cox proportional hazard regression analysis. During a median follow-up time of 11.3 years and a total of 90 635 person years, 1868 of the 6130 individuals died (30.5%), of whom 442 (23.7%) died because of cardiovascular disease. In individuals with low ADAMTS13 activity, the risk of cardiovascular mortality (hazard ratio, 1.46; 95% confidence interval, 1.09-1.96) was higher than that in individuals with high ADAMTS13 activity. The risk of cardiovascular mortality (hazard ratio, 1.29; 95% confidence interval 0.98-1.70) was higher in individuals with the highest VWF:Ag levels than in those with the lowest levels. In individuals with both low ADAMTS13 activity and high VWF:Ag levels, the risk of cardiovascular mortality was even higher (hazard ratio, 1.73 95% confidence interval, 1.28-2.35). CONCLUSIONS: In this large prospective cohort study, ADAMTS13 activity and VWF:Ag levels are both associated with an increased risk of all-cause and cardiovascular mortality.
OBJECTIVE:Von Willebrand Factor (VWF) is a plasma protein that plays a major role in platelet adhesion and aggregation. Large VWF multimers are cleaved into smaller, less coagulant forms by the metalloprotease ADAMTS13 (A Disintegrin And Metalloprotease with ThromboSpondin motif repeats 13). Previous studies have shown that high VWF and low ADAMTS13 levels are associated with cardiovascular disease, but whether these factors are associated with mortality is unclear. Our aim is to establish the association between VWF antigen (VWF:Ag) levels, ADAMTS13 activity, and mortality. APPROACH AND RESULTS: We included 6130 participants of the Rotterdam study, a population-based cohort study among individuals aged ≥55 years. We determined the association between ADAMTS13 activity, VWF:Ag levels, and all-cause and cardiovascular mortality by Cox proportional hazard regression analysis. During a median follow-up time of 11.3 years and a total of 90 635 person years, 1868 of the 6130 individuals died (30.5%), of whom 442 (23.7%) died because of cardiovascular disease. In individuals with low ADAMTS13 activity, the risk of cardiovascular mortality (hazard ratio, 1.46; 95% confidence interval, 1.09-1.96) was higher than that in individuals with high ADAMTS13 activity. The risk of cardiovascular mortality (hazard ratio, 1.29; 95% confidence interval 0.98-1.70) was higher in individuals with the highest VWF:Ag levels than in those with the lowest levels. In individuals with both low ADAMTS13 activity and high VWF:Ag levels, the risk of cardiovascular mortality was even higher (hazard ratio, 1.73 95% confidence interval, 1.28-2.35). CONCLUSIONS: In this large prospective cohort study, ADAMTS13 activity and VWF:Ag levels are both associated with an increased risk of all-cause and cardiovascular mortality.
Authors: Qianyi Ma; Paula M Jacobi; Brian T Emmer; Colin A Kretz; Ayse Bilge Ozel; Beth McGee; Chava Kimchi-Sarfaty; David Ginsburg; Jun Z Li; Karl C Desch Journal: Blood Adv Date: 2017-06-19
Authors: M Arfan Ikram; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Stricker; Henning Tiemeier; André G Uitterlinden; Meike W Vernooij; Albert Hofman Journal: Eur J Epidemiol Date: 2017-10-24 Impact factor: 8.082
Authors: Harshvardhan Upreti; Jamil Kasmani; Kathryn Dane; Evan M Braunstein; Michael B Streiff; Satish Shanbhag; Alison R Moliterno; C John Sperati; Rebecca F Gottesman; Robert A Brodsky; Thomas S Kickler; Shruti Chaturvedi Journal: Blood Date: 2019-08-20 Impact factor: 22.113
Authors: Max A Brodsky; Senthil Sukumar; Sruthi Selvakumar; Lisa Yanek; Sarah Hussain; Marshall A Mazepa; Evan M Braunstein; Alison R Moliterno; Thomas S Kickler; Robert A Brodsky; Spero R Cataland; Shruti Chaturvedi Journal: Am J Hematol Date: 2021-09-15 Impact factor: 10.047
Authors: Gurbey Ocak; Mark Roest; Marianne C Verhaar; Maarten B Rookmaaker; Peter J Blankestijn; Willem Jan W Bos; Rob Fijnheer; Nathalie C Péquériaux; Friedo W Dekker Journal: BMC Nephrol Date: 2021-06-16 Impact factor: 2.388